Pharmacy Innovations
Has Pharmacy Innovations received an FDA warning letter about GLP-1 drugs?
No FDA warning letter to Pharmacy Innovations naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 1 drug recall report for it naming semaglutide, the latest initiated Dec 22, 2022.
FDA records in this index name Pharmacy Innovations on Dec 22, 2022.
- Type named in FDA records
- Not stated
- FDA warning letters
- 0
- Drug recall reports
- 1
- Drugs named
- Semaglutide
- Latest record
- Dec 22, 2022
FDA warning letters
No FDA warning letters in this index.
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Dec 22, 2022 | SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 2MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 4MG/ML (0.5ML ... | Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility. | Class II | Terminated | D-0236-2023 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.